dm+d

Unassigned

New Medicines

Uncomplicated gonorrhoea

Information

New molecular entity
Entasis Therapeutics
Entasis Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

First in class inhibitor of DNA gyrase (topoisomerase type II)
Gonorrhoea diagnoses in the UK increased by 80% between 2013 and 2018; up to mid-2019 resistance to first-line antibacterials, including ceftrixone and azithromycin, continued to increase from previous levels. Azithromycin resistance has reached the point where it is no longer recommended as first-line therapy [2].
Uncomplicated gonorrhoea
Oral